The concentrating on of each the muscarinic and β-adrenergic pathways is a effectively validated therapeutic strategy for the therapy of power obstructive pulmonary illness (COPD). On this communication we report our effort to include two pharmacologies right into a single chemical entity, whose attribute should be appropriate for a as soon as every day inhaled administration. Contextually, we aimed toward a domestically performing remedy with restricted systemic absorption to reduce negative effects. Our lung-tailored desing of bifunctional compounds that mix the muscarinic and β-adrenergic pharmacologies by the elaboration of the muscarinic inhibitor 7, efficiently led to the potent, pharmacologically balanced muscarinic antagonist and β2 agonist (MABA) 13.
Acute kidney harm (AKI) and power kidney illness are widespread interconnected syndromes that symbolize a public well being drawback. Acute kidney illness (AKD) is outlined because the post-AKI standing of acute or subacute kidney injury/dysfunction manifested by persistence of AKI past 7 to 90 days after the preliminary AKI analysis. Restricted scientific knowledge exist concerning AKD epidemiology however its incidence is noticed in ∼25% of AKI survivors. Helpful risk-stratification instruments to foretell danger of AKD and its prognosis are wanted. Interventions on fluid administration, nephrotoxic publicity, and follow-up care maintain promise to ameliorate the burden of AKD and its issues.
Affiliation between power kidney illness (CKD) and ischaemic coronary heart illness (IHD) is well-known. Clinically, due to using intra-arterial distinction, coronary angiograms are generally not carried out to keep away from additional deterioration in kidney operate amongst CKD sufferers. Due to this fact, our purpose is to establish whether or not intervention for non-ST elevation myocardial infarction (NStemi) is related to elevated mortality or additional renal deterioration. Power obstructive pulmonary illness (COPD) is usually accompanied by psychiatric issues, equivalent to despair and anxiousness, affecting each therapy outcomes and mortality. Proof for the variety of COPD sufferers utilizing remedy for these problems is sparse. On this examine, power antidepressant (ATD) and anxiolytic (ANX) drug use – to establish despair and anxiousness – amongst COPD sufferers was in contrast with topics with or with out different power illnesses.
Affiliation between the transtubular potassium gradient and development of power kidney illness: outcomes from KNOW-CKD
The transtubular potassium gradient which displays potassium secretion by the kidney by the cortical gathering duct, has not but been examined as a surrogate marker of kidney operate decline. Right here, we examine the connection between the transtubular potassium gradient and power kidney illness (CKD) development. We studied 1672 sufferers from the KoreaN Cohort Examine for Final result in Sufferers With Power Kidney Illness (KNOW-CKD) cohort. The transtubular potassium gradient was calculated utilizing a regular equation. The examine endpoint was CKD development, outlined as a composite of a ≥ 50% lower in estimated glomerular filtration fee (eGFR) from baseline values or end-stage kidney illness.
Throughout a median follow-up of 4.1 years (7149 person-years), 441 contributors reached the endpoint. In cause-specific competing danger evaluation, the best tertile was related to a considerably decrease danger of an opposed kidney consequence in contrast with the bottom tertile [hazard ratio (HR), 0.73; 95% confidence interval (CI), 0.55-0.97]. When the transtubular potassium gradient was handled as a steady variable, a rise of 1 within the transtubular potassium gradient was related to a 6% decrease danger of CKD development (95% CI, 0.90-0.99). This affiliation was significantly evident in sufferers with an eGFR ≥ 45 mL/min/1.73 m2. A time-updated transtubular potassium gradient mannequin confirmed comparable outcomes.
The predictive efficiency of the transtubular potassium gradient was considerably lower than that of the eGFR, however much like that of proteinuria, serum bicarbonate, and urine osmolality. The next transtubular potassium gradient is related to a considerably decrease danger of CKD development, suggesting that it might supply insights into the prognosis of CKD. Moreover, the serum ranges of FGF23 and Klotho are affected by numerous components, and the degrees of FGF23 and Klotho in CKD sufferers are negatively correlated. GFR, serum creatinine,
Significance of Power Illnesses and Smoking Habits within the Improvement of Acute Respiratory Misery Syndrome Amongst Hospitalized COVID-19 Sufferers in Indonesia
Acute respiratory misery syndrome (ARDS) is without doubt one of the important causes of excessive mortality amongst coronavirus illness 2019 (COVID-19) sufferers. This examine aimed toward figuring out the affiliation between presence of power illnesses and smoking behaviors with the event of ARDS amongst hospitalized COVID-19 sufferers in Indonesia. This examine was carried out in 15 Muhammadiyah-‘Aisyiyah-affiliated COVID-19 referral hospitals in Indonesia. 4 hundred ninety contributors who examined constructive for the COVID-19 had been recruited on this examine.
Demographic knowledge, historical past of power illnesses, and the event of ARDS had been retrieved from hospital affected person data. Details about the smoking conduct was collected after respondents had been discharged from the hospital. Presence of power illnesses equivalent to diabetes, power coronary heart illness, hypertension, and power liver illnesses had been considerably related to the event of ARDS. In an analogous regard, sufferers who at present smoked had a 5 occasions higher danger of creating ARDS in contrast with those that by no means smoked.
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC942046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF594 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCA2035-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), APC conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCA2046-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), APC conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC812035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC812035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC812046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC812046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCAP2035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCAP2035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCAP2046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCAP2046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC472035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF647 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC472035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF647 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC472046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF647 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC472046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF647 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC432035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF543 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC432035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF543 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC432046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF543 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC432046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF543 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC882035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF488A conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC882035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF488A conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC882046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF488A conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC882046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF488A conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCH2035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCH2035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCH2046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCH2046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCP2035-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), PerCP conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCP2046-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), PerCP conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC042035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405S conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC042035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405S conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC042046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405S conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC042046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405S conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCR2035-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), RPE conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCR2046-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), RPE conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNUB2035-100 | Biotium | 100uL | EUR 264 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Concentration: 0.2mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNUB2035-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNUB2035-500 | Biotium | 500uL | EUR 513 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Concentration: 0.2mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNUB2046-100 | Biotium | 100uL | EUR 264 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Concentration: 0.2mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNUB2046-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNUB2046-500 | Biotium | 500uL | EUR 513 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Concentration: 0.2mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC612035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF660R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC612035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF660R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC612046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF660R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC612046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF660R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC682035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF568 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC682035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF568 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC682046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF568 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC682046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF568 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC702035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF770 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC702035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF770 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC702046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF770 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC702046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF770 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC052035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405M conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC052035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405M conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC052046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405M conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC052046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405M conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC552035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF555 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC552035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF555 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC552046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF555 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC552046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF555 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC402035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF640R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC402035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF640R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC402046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF640R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC402046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF640R conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC802035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNC802035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC802046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNC802046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680 conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCB2035-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Biotin conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
|||
| BNCB2035-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Biotin conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCB2046-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Biotin conjugate, Concentration: 0.1mg/mL |
|||
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
|||
| BNCB2046-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Monoclonal ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody, Clone: SPM362 |
|||
| APR14716G | Leading Biology | 7 ml | EUR 484 |
|
Description: A Monoclonal antibody against Human ZAP70 (Chronic Lymphocytic Leukemia Marker). The antibodies are raised in Mouse and are from clone SPM362. This antibody is applicable in IHC, IF, FC |
|||
Monoclonal ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody, Clone: 2F3.2 |
|||
| APR14717G | Leading Biology | 7 ml | EUR 484 |
|
Description: A Monoclonal antibody against Human ZAP70 (Chronic Lymphocytic Leukemia Marker). The antibodies are raised in Mouse and are from clone 2F3.2. This antibody is applicable in IHC, IF, FC |
|||
Cancer MicroRNA qPCR Array |
|||
| RA610A-1 | SBI | 10 profiles | EUR 1172 |
Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E02C1802-192T | BlueGene | 192 tests | EUR 1270 |
|
Description: A sandwich ELISA for quantitative measurement of Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E02C1802-48 | BlueGene | 1 plate of 48 wells | EUR 520 |
|
Description: A sandwich ELISA for quantitative measurement of Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E02C1802-96 | BlueGene | 1 plate of 96 wells | EUR 685 |
|
Description: A sandwich ELISA for quantitative measurement of Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Chronic Lymphocytic Leukemia Deletion Region Gene 8 Protein (CLLD8) Antibody |
|||
| abx430501-200ul | Abbexa | 200 ul | EUR 384 |
Monoclonal ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody, Clone: ZAP70/528 |
|||
| APR14715G | Leading Biology | 7 ml | EUR 484 |
|
Description: A Monoclonal antibody against Human ZAP70 (Chronic Lymphocytic Leukemia Marker). The antibodies are raised in Mouse and are from clone ZAP70/528. This antibody is applicable in IHC, IF, FC |
|||
ZAP-70 (Chronic Lymphocytic Leukemia Marker); Clone ZAP70/528 (Concentrate) |
|||
| RA0453-C.1 | ScyTek Laboratories | 0.1 ml | EUR 125 |
ZAP-70 (Chronic Lymphocytic Leukemia Marker); Clone ZAP70/528 (Concentrate) |
|||
| RA0453-C.5 | ScyTek Laboratories | 0.5 ml | EUR 300 |
ZAP-70 (Chronic Lymphocytic Leukemia Marker); Clone ZAP70/528 (Concentrate) |
|||
| RA0453-C1 | ScyTek Laboratories | 1 ml | EUR 500 |
Monoclonal ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody, Clone: ZAP70/528 + 2F3.2 |
|||
| APR14714G | Leading Biology | 7 ml | EUR 484 |
|
Description: A Monoclonal antibody against Human ZAP70 (Chronic Lymphocytic Leukemia Marker). The antibodies are raised in Mouse and are from clone ZAP70/528 + 2F3.2. This antibody is applicable in IHC, IF, FC |
|||
Dog Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E08C1802-192T | BlueGene | 192 tests | EUR 1270 |
|
Description: A sandwich ELISA for quantitative measurement of Canine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E08C1802-48 | BlueGene | 1 plate of 48 wells | EUR 520 |
|
Description: A sandwich ELISA for quantitative measurement of Canine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E08C1802-96 | BlueGene | 1 plate of 96 wells | EUR 685 |
|
Description: A sandwich ELISA for quantitative measurement of Canine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E06C1802-192T | BlueGene | 192 tests | EUR 1270 |
|
Description: A sandwich ELISA for quantitative measurement of Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E06C1802-48 | BlueGene | 1 plate of 48 wells | EUR 520 |
|
Description: A sandwich ELISA for quantitative measurement of Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E06C1802-96 | BlueGene | 1 plate of 96 wells | EUR 685 |
|
Description: A sandwich ELISA for quantitative measurement of Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E04C1802-192T | BlueGene | 192 tests | EUR 1270 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E04C1802-48 | BlueGene | 1 plate of 48 wells | EUR 520 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E04C1802-96 | BlueGene | 1 plate of 96 wells | EUR 685 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E03C1802-192T | BlueGene | 192 tests | EUR 1270 |
|
Description: A sandwich ELISA for quantitative measurement of Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
|||
| E03C1802-48 | BlueGene | 1 plate of 48 wells | EUR 520 |
|
Description: A sandwich ELISA for quantitative measurement of Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Many sufferers with power fatigue syndrome (CFS) fail to derive profit from evidence-based remedies equivalent to cognitive-behavioural remedy (CBT) and graded train remedy resulting in everlasting incapacity. To find whether or not a repeat prescription of modafinil would possibly potentiate the advantages of CBT resulting in social restoration as outlined by 2 or extra level enchancment in vitality and muscular ache/focus and return to work or full-time coaching. Three sufferers with treatment-resistant CFS (imply length 17.66 years) handled with modafinil and CBT in a Liaison Psychiatry clinic had been retrospectively reviewed.